# A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

> **NCT00509873** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 578 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** Gatifloxacin 0.5% eye drops
- **DRUG:** placebo eye drops

## Key facts

- **NCT ID:** NCT00509873
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 578 (ACTUAL)
- **Last updated:** 2011-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509873, "A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00509873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*